A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB

NCT07095855 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

1300

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

DRUG: ZM-H1505R 100mg
OTHER: ZM-H1505R Placebo
COMBINATION_PRODUCT: NAs （"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF"） treatments

Sponsor

Shanghai Zhimeng Biopharma, Inc.